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Abstract
Background: Immunization of mice with the Trypanosoma cruzi trans-sialidase (TS) gene using plasmid DNA, adenoviral
vector, and CpG-adjuvanted protein delivery has proven highly immunogenic and provides protection against acute lethal
challenge. However, long-term protection induced by TS DNA vaccines has not been reported. The goal of the present work
was to test whether the co-administration of a plasmid encoding IL-15 (pIL-15) could improve the duration of protection
achieved through genetic vaccination with plasmid encoding TS (pTS) alone.
Methodology: We immunized BALB/c mice with pTS in the presence or absence of pIL-15 and studied immune responses
[with TS-specific IFN-c ELISPOT, serum IgG ELISAs, intracellular cytokine staining (IFN-c, TNF-a, and IL-2), tetramer staining,
and CFSE dilution assays] and protection against lethal systemic challenge at 1 to 6 months post vaccination. Mice receiving
pTS alone developed robust TS-specific IFN-c responses and survived a lethal challenge given within the first 3 months
following immunization. The addition of pIL-15 to pTS vaccination did not significantly alter T cell responses or protection
during this early post-vaccination period. However, mice vaccinated with both pTS and pIL-15 challenged 6 months post-
vaccination were significantly more protected against lethal T. cruzi challenges than mice vaccinated with pTS alone
(P,0.05). Improved protection correlated with significantly higher numbers of TS-specific IFN-c producing total and CD8+ T
cells detected.6 months post immunization. Also, these TS-specific T cells were better able to expand after in vitro re-
stimulation.
Conclusion: Addition of pIL-15 during genetic vaccination greatly improved long-term T cell survival, memory T cell
expansion, and long-term protection against the important human parasite, T. cruzi.
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Introduction
Over 11 million individuals are infected worldwide with
Trypanosoma cruzi, and over 50,000 deaths are attributed to this
protozoan parasite annually [1]. Human infection usually occurs
through contact with T. cruzi contaminated triatomine excreta,
although the parasite also can be transmitted via congenital and
parenteral routes or by organ donation [2]. Acute infection,
usually associated with only mild and nonspecific symptoms
including fever, fatigue, and high parasitemia, often goes
undiagnosed. Although high level parasitemia and symptoms
resolve after 3–8 weeks, low level tissue parasitism persists for
decades, leading to pathologic manifestations of Chagas disease
including cardiomyopathy and the mega-syndromes (mega-
esophagus and mega-colon) in 30–50% of chronically infected
individuals. Chemotherapy with benznidazole and nifurtimox can
be highly successful if used within the first several weeks of
infection, but rarely leads to cure during chronic infection, and
toxic side effects limit their use. Because of the high risk of
infection and disease in endemic countries and the lack of well
tolerated trypanocidal drugs, a safe and effective vaccine is needed.
Several T. cruzi antigens, including trans-sialidase (TS), have
been used successfully as experimental vaccines to reduce acute T.
cruzi infection and chronic inflammation in mice [3–10]. TS, a
member of the largest T. cruzi gene family (.1400 genes), is
expressed on blood form trypomastigotes (BFT) and metacyclic
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trypomastigotes (MT), and is also present during early and late
stage intracellular infection [11,12]. T. cruzi is unable to synthesize
sialic acid, which seems to be required for parasite infectivity. TS
cleaves sialic acid from host cell donor molecules and transfers the
released sialic acid onto the parasite surface. Vaccines incorpo-
rating TS (expressed in adenoviral vectors, in DNA vaccines, or
purified recombinant protein mixed with toll-like receptor-9 CpG
motifs) induce robust CD4+ and CD8+ T cell as well as antibody
responses in mice, and more importantly, can protect against
lethal T. cruzi challenge [3,13]. However, only short term TS
vaccine-induced protection has been reported.
Interleukin-15 (IL-15) is one of the so-called ‘homeostatic’
cytokines, which is beneficial for long-term survival of memory T
cells. The functions of IL-15 are similar to that of IL-2, although
these two cytokines do not have amino acid homology. IL-15 is
synthesized by many types of cells including monocytes,
macrophages, epithelial, and dendritic cells, but is not expressed
by T cells. Central memory T cells (Tcm) express the receptor for
IL-15 (IL-15R), and have the capacities to both extensively
proliferate and produce key effector molecules after antigenic
restimulation. These central memory T cells are critical for long-
term protective immunity. In this work, we describe the
enhancement of long term CD8+ T cell responses and protective
T. cruzi immunity in mice (.6 months post vaccination) after
vaccination with a combination of DNA vaccines encoding both
TS and IL-15.
Materials and Methods
Ethics
All animal studies were approved by the Institutional Animal
Care and Use Committee (IACUC)/Animal Care Committee
(ACC) at Saint Louis University. The University is registered with
the USDA as a research facility (43-R-011), is regularly inspected
and files an annual report. In addition, under the provisions of the
Public Health Service Policy on the Humane Care and Use of
Laboratory Animals, revised September 1986, the University has
filed the appropriate assurance documents. (Assurance number A-
3225-01). The facilities and programs for the use of animals at
Saint Louis University are FULLY ACCREDITED by the
American Association for the Accreditation of Laboratory Animal
Care (AAALAC). The date of our most recent notification was
June 18, 2009.
Parasites and mice
Six to eight week old female BALB/c mice were used
throughout these studies (Charles River/NCI). Tulahue´n strain
T. cruzi blood form trypomastigotes (BFT) were prepared by bi-
weekly passage through BALB/c mice as previously described
[14,15].
Optimized IL-15 gene construction
The murine interleukin-15 (IL-15) gene (genbank accession
number BC023698) containing the long signal peptide (LSP) was
cloned into the Invitrogen pVAX-1 vector (pIL-15LSP), and used
as the PCR template for subsequent subcloning strategies. The
LSP of IL-15 was replaced with an optimized signal peptide
incorporating an efficient Kozak sequence and the 18aa signal
peptide derived from Homo Sapiens immunoglobulin secretory
leader signal as previously described [16–18]. This was accom-
plished using PCR primers 59-GCCCCCGGATCCGCCGC-
CACCATGGATTGGACTTGGATCTTATTTTTAGTTGCT-
GCTGCTACTAGAGTTCATTCTAACTGGATAGATGTAA-
GATAT-39 and 59-GCCCCCGAATTCTCAGGACGTGTT-
GATGAACATTTG-39. The resulting PCR product was sub-
cloned into pVAX-1 using BamH1 and EcoR1 restriction sites (pIL-
15opt, later referred to as pIL-15). Plasmids (pVAX, pIL-15LSP,
and pIL-15opt) were propagated in DH5a strain E. coli and purified
using QIAGEN plasmid purification kits (Valencia, CA).
Measurement of IL-15 expression in COS-7 cells
COS-7 cells (ATCC, Manassas, VA) were transfected with
pVAX, pIL-15LSP, or pIL-15opt using Lipofectamine 2000
transfection reagent (Invitrogen) as recommended by the manu-
facturer. After 48 hours, cell lysates were prepared for use in IL-
15-specific western blots and IL-15 bioassays. Western blots were
performed using biotinylated goat anti-mouse IL-15 and strepta-
vidin-HRP, followed by development with Luminol chemilumi-
nescent substrate. In addition, lysates from transfected COS-7 cells
were added to 96 well flat bottom plates containing 56103 CTLL-
2 cells (IL-15 sensitive cell line, ATCC) and incubated at 37uC for
24 hours prior to the addition of 0.5 mCi [3H] thymidine. After
24 hours, cells were harvested onto glass fiber filtermats using a
Tomtec Mach-IIIM automated cell harvester, Ultima Gold F
scintillation fluid added, and radioactive incorporation measured
using a Wallac Microbeta 1450 scintillation counter [3]. A
standard curve of mIL-15 was generated using purified rmIL-15,
and employed to determine levels of functional IL-15 present in
transfected COS-7 cell lysates (reported in ng/ml).
Plasmid DNA vaccination of mice
Negative control (pcDNA), Trans-sialidase (pTS; genbank
D50685, GI 840707 described in [19]) and IL-15 optimized
(pIL-15) plasmids were prepared using QIAGEN EndoFree
Plasmid Giga kits as per manufacturer recommendations. Plasmids
were suspended at a concentration of 2 mg/ml in sterile endotoxin
free PBS. Endotoxin levels were ,1 endotoxin unit/ml as
determined by LAL assay (Associates of Cape Cod, East
Falmouth, MA). Mice were anesthetized intraperitoneally with
ketamine (60 mg/kg) and xylazine (5 mg/kg), then vaccinated i.m.
(tibialis anterior, 50 ml per limb) three times at two week intervals
with a total of 200 mg plasmid DNA (100 mg pcDNA + 100 mg
pIL-15, 100 mg pcDNA + 100 mg pTS, or 100 mg pIL-15 + 100 mg
Author Summary
Over 11 million individuals are infected with Trypanosoma
cruzi, the causative agent of Chagas disease, which kills
.50,000 people annually. Although recent vector control
efforts and increased use and effectiveness of chemother-
apeutic drugs including benznidazole have reduced
infection rates and mortality, a safe, effective vaccine is
needed. Vaccination with the T. cruzi trans-sialidase (TS)
has been used effectively in mice to reduce mortality and
chronic disease, however, the establishment of vaccine-
induced long-term protective immunity remains elusive.
Co-immunization strategies utilizing immune regulators
such as interleukin-12 (IL-12) and interleukin-15 (IL-15) can
be used to enhance antigen-specific T cell responses and
prolong protective immunity. In the present report, we
show that genetic vaccination of BALB/c mice with
plasmid DNA encoding both TS and IL-15 compared with
plasmid DNA encoding TS alone significantly enhanced
CD4+ and CD8+ T cell responses including increased TNF-a,
IFN-c, and IL-2 production, and long-term protection
against lethal systemic parasite challenge.
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pTS). Representative mice were harvested 1, 3, or 6 months after
their final immunization to assess vaccine-induced immune
responses. Other mice (N = 5–10 per group) were challenged with
5,000 BFT subcutaneously and survival followed for . 2 months.
Quantitation of IFN-c secreting cells by ELISPOT
One to six months after the third and final vaccination, spleen
cells from representative vaccinated mice were stimulated in IFN-c
ELISPOT assays. Spleen cells (3–56105 per well) plus antigen
presenting cells {16105 A20J cells alone (ATCC), A20J cells
pulsed with 2.5 mg/ml of the immunogenic CD8+ H2Kd restricted
TS peptide IYNVGQVSI (TSaa359-367;ResGen/Invitrogen)
[3,20], or A20J transfected with the TS gene [21]} were cultured
in anti-IFN-c coated BD Biosciences, San Jose, CA) and blocked
nitrocellulose bottom ELISPOT plates [using T-cell+ media: 10%
FBS (Thermo Scientific Hyclone, Logan, UT), 50% EHAA
(Invitrogen, Carlsbad, CA), 37% RPMI (Invitrogen) 50 U/ml
penicillin + 50 mg/ml streptomycin (Lonza Inc., Allendale, NJ),
2 mM L-Glutamine (Lonza), 50 mM 2-mercaptoethanol (Sigma,
St. Louis, MO), and 50 mg/ml gentamycin (Lonza)]. After
overnight stimulation, wells were subsequently incubated with 1)
biotinylated-anti-mouse IFN-c BD Biosciences), 2) streptavidin-
HRP (Jackson Immunoresearch Laboratories, West Grove, PA), 3)
and AEC substrate (Sigma). Images of developed ELISPOT plates
were captured using a CTL Analyzer and spots counted using
Immunospot Software v3.2 (CTL, Shaker Heights, OH). Data are
represented as the number of IFN-c spot forming cells (SFC) per
million total spleen cells (TSC) or SFC per million CD8+ T cells.
TS-specific IgG ELISA
TS-specific serum IgG responses were measured by ELISA in
samples collected from individual mice 1, 3, and 6 months post-
immunization as previously described [3]. Endpoint titers were
determined using Unitwin Opticalc software (PhPlate AB, Stock-
holm Sweden) based upon transformed O.D. and dilution curves
using a 0.2 O.D. cutoff.
Measurement of cytokine producing cells by intracellular
cytokine staining (ICS) and flow cytometry
Spleen cells (26106/ml) from mice vaccinated 6 months prior
were stimulated with 16105/ml A20J cells or A20J transfected
with TS (A20-TS) in round bottom culture tubes. After overnight
culture, monensin and brefeldin-A were added as recommended
by the manufacturer (GolgiPlug and GolgiStop, respectively, BD
Biosciences). In order to study polyclonal T cell responses, cells
were rested overnight prior to addition of phorbol-12-myristate
13-acetate (PMA, 10 ng/ml), ionomycin (500 ng/ml), monensin,
and brefeldin-A for the final 3 hours of culture. Cells were then
washed with PBS, stained using LIVE/DEAD fixable Aqua Stain
cell reagent, (Invitrogen), Fc receptors blocked by incubation with
anti-CD16/32 (15 minutes, 4oC), then surface stained at 4oC for
30 minutes using CD3-FITC, CD8-PerCP, CD4-Pacific Blue, and
TS(IYNVGQVSI)/H2Kd-tetramer-APC (all antibodies were pur-
chased from BD Biosciences unless noted otherwise, and the
IYNVGQVSI-specific APC tetramer reagent was provided
through the NIH Tetramer Core Facility, Atlanta, GA). BD
Cytoperm/Cytofix was used to fix and permeablize the cells as per
manufacturer suggestions prior to staining with IL-2-PE, IFN-c-
Alexa700 and TNF-a-PE-Cy7 (30 minutes at 4oC). Cells were
then washed and resuspended in permeabilization buffer prior to
acquisition on a LSR-II flow cytometer (BD). Data sets were
analyzed using FLOWJO Flow Cytometry Analysis v7 software
(Tree Star, Inc., Ashland, OR).
Analysis of TS(IYNVGQVSI)/H2Kd tetramer positive cells
Six months following immunization, spleen cells were stained
directly ex vivo using the surface staining procedure described
above. Additionally, spleen cells were stained with CFSE (Vybrant
CFDA SE cell tracer, Invitrogen), washed 3 times, and cultured
(26106/ml) with irradiated (12,500 rads) A20J or A20-TS cells
(16105) for 6 days at 37oC using the same media as described
above (T-cell+). Cells were then washed and stained for CD3,
CD8, CD4, and TS(IYNVGQVSI)/H2Kd tetramer binding prior to
flow cytometric analysis as described above. Absolute numbers
(AN) of TS(IYNVGQVSI)/H2Kd tetramer positive cells present in
expanded cultures were determined as follows: total cell yield after
expansion as determined by trypan blue cell count 6 (# of
TS(IYNVGQVSI)/H2Kd tetramer positive events 4 number of
live events collected). These ANs were used to calculate the
antigen-specific AN index (AN Index = absolute number of
TS(IYNVGQVSI)/H2Kd tetramer positive cells after A20-TS expan-
sion 4 absolute number of TS(IYNVGQVSI)/H2Kd-tetramer
positive cells present after NC A20 expansion).
Adoptive transfer studies
Adenoviral vectors (type 5) encoding TS (Adeno-TS) were
constructed as described previously [13]. HEK293A cells were
grown at 37oC to 80% confluency in T150 flasks using 10% FBS
in DMEM supplemented with penicillin, streptomycin, and L-
glutamine. Flasks were inoculated with recombinant adenovirus
diluted in 5 ml of DMEM alone. After 2 hours, complete media
was added and infected cells cultured until cytopathic effect
observed (usually 48 hours after infection). Cells were manually
detached and pooled (20 flasks/prep), pelleted by centrifugation,
supernatants discarded, and cells resuspended in 20 ml of
complete DMEM. Cells were freeze-thawed 3 times, sonicated
for 3 minutes (3 times), and centrifuged at 17,0006g for
10 minutes at 4oC. CsCl was added to 0.51 g/ml, mixed for
20 minutes at room temperature, and centrifuged at 110,0006g
for 24 hours at 4oC. Adenovirus bands were collected, dialyzed
into 20 mM Tris, pH 8.0 (10,000 MWCO, 3 exchanges), and
glycerol added (final concentration 10%) prior to storage at
280oC. Standard TCID50 assays using HEK293A cells were used
to determine adenovirus stock concentrations.
BALB/c mice were vaccinated i.m. on days 0 and 14 with
100 mg of pTS alone, and boosted on days 42 and 56 with 16108
pfu of Adeno-TS s.c. Two months later, spleen cells were
harvested from TS prime-boost vaccinated mice and CD8+ T
cell fractions prepared using positive-selection standard magnetic
bead separation techniques (Miltenyi Biotec, Bergisch Gladbach,
Germany ; typical CD8+ fraction purities exceeded 98%).
Functionality of CD8+ T cells was confirmed by IFN-c ELISPOT
as described above. Purified CD8+ T cells were injected i.p. into
naı¨ve BALB/c recipient mice (2.66107 per mouse), and mice
challenged 24 hours later with 5,000 BFT s.c.
Statistical analyses
Data sets were analyzed using Statistica v. 6.0 (Statsoft, Inc.,
Tulsa, OK). Tests performed include Mann Whitney U tests,
Fisher’s exact tests, and Wilcoxon Matched pairs tests.
Results
Construction and functional testing of the IL-15 plasmid
DNA
The murine IL-15 gene containing the long signal peptide (LSP)
was cloned into the mammalian expression plasmid pVAX as
described in Materials and Methods. We inserted an optimized
IL-15-Adjuvanted T. cruzi Vaccine Studies
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signal sequence for IL-15 which includes a stronger Kozak
sequence, removal of upstream inhibitory AUG sequences, and
changed the LSP to the Homo Sapiens immunoglobulin secretory
leader signal as previously described [16–18]. The complete amino
acid sequences and protein schematics of the IL-15 genes are
shown in Figs. 1A and 1B. Plasmid DNA encoding murine IL-15
sequences with or without the upstream optimization sequence
(pIL-15LSP and pIL-15opt, respectively) were transiently trans-
fected into COS-7 cells, and after 48 hours cell lysates were
prepared and analyzed for IL-15 expression using IL-15-specific
western blots and IL-15-sensitive cells (CTLL-2 bioassays). COS-7
cells transfected with the optimized IL-15 plasmid but not with the
pVAX alone expressed IL-15 as shown by western blot (Fig. 1C).
The functional activity of the COS-7 synthesized IL-15 is shown in
Fig. 1D. These results demonstrate that the cloned optimized
murine IL-15 gene can be highly expressed and has potent
functional activity in mammalian cells (pIL-15opt referred to as
pIL-15 hereafter).
Figure 1. Construction and evaluation of IL-15 expression plasmids. Shown in panels A and B are amino acid alignments and mature protein
schematics of the murine IL-15 genes containing the long signal peptide (LSP) and optimized signal sequence (opt). These proteins were cloned into the
eukaryotic expression plasmid pVAX and resulting plasmids transfected into COS-7 cells. After 48 hours, lysates from pVAX and pIL-15opt transfected
COS-7 cells were prepared and analyzed by western blot along with recombinant murine IL-15 (rmIL-15, panel C). COS-7 cells transfected with pIL-15opt
resulted in high level expression of murine IL-15. IL-2/IL-15 dependent cells (CTLL-2) were cultured in 96 well plates with transfected COS-7 lysates in
order to determine the functionality of the cloned IL-15 constructs. Purified recombinant IL-15 was utilized as a positive control and used to prepare a
standard curve. After 24 hours of culture, 3H-thymidine was added and one day later plates were harvested, scintillated, and radioactive incorporation
measured. COS-7 cells transfected with pIL-15opt express functionally active IL-15 as determined using this CTLL-2 bioassay (D).
doi:10.1371/journal.pntd.0000983.g001
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Immunization with trans-sialidase DNA induces robust
TS-specific IFN-c responses and protection against lethal
T. cruzi challenge given 1 month post-vaccination
We have previously shown that immunization using plasmid
DNA encoding TS or recombinant TS protein (rTS) mixed with
CpG adjuvant induces strong TS-specific IFN-c responses and
protection against lethal systemic T. cruzi challenge [3]. In order to
demonstrate the effectiveness of vaccination with IL-15-adju-
vanted TS, BALB/c mice were immunized with pcDNA + pIL-15,
pcDNA + pTS, or pIL-15 + pTS as described above. Thirty days
after the final vaccination spleen cells from representative mice
were stimulated with antigen presenting cells permanently
transfected (or not) with DNA encoding TS in IFN-c ELISPOT
Figure 2. T cell responses and protective immunity at 30 days post pTS ± IL-15 vaccination. BALB/c mice were vaccinated i.m. 3 times, 2
weeks apart, with plasmids encoding TS (pTS) and/or IL-15 (pIL-15). Thirty days after the final vaccination, spleen cells from representative mice were
incubated for 16–20 hours in the presence of negative control antigen presenting cells (NC A20), or antigen presenting cells stably transfected with
full length TS (A20-TS) in IFN-c ELISPOT assays. In addition, 5 mice per group were challenged with 5,000 BFT s.c. and survival monitored for . 2
months. Mice vaccinated with pTS (regardless of inclusion of pIL-15) produced high numbers of TS-specific IFN-c secreting cells (A, pooled cells from
2 mice per group). Additionally, 100% of mice vaccinated with pTS or pTS+pIL-15 survived lethal systemic T. cruzi challenge, whereas all mice
vaccinated with control plasmids succumbed to infection (B, * P,0.05 by Fisher’s exact tests in comparison to pIL-15 alone group). Data
representative of 3 experiments.
doi:10.1371/journal.pntd.0000983.g002
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assays {A20 and A20-TS, [21]}. Regardless of co-immunization
with pcDNA or pIL-15, all mice vaccinated with pTS generated
similar numbers of TS-specific IFN-c secreting T cells detectable
at the 1 month post-vaccination time point (Fig. 2A). In addition,
spleen cells from all groups of mice receiving pTS vaccination
contained similar numbers of IYNVGQVSI-specific CD8+ T cells
as indicated by IFN-c ELISPOT (1.161.1, 51.167.3, and
54.464.8 TSIYNVGQVSI-specific IFN-c spot forming cells per
million spleen cells in pIL-15 control, pTS alone, and pTS + pIL-
15 vaccinated mice, respectively). We were unable to detect
differences in TS-specific IgG responses in sera from pTS and
pTS + pIL-15 vaccinated mice (endpoint titers of .90,000 in pTS
alone and pTS + pIL-15 vaccinated mice, compared to ,100
detected in samples from pIL-15 alone vaccinated mice). In order
Figure 3. T cell responses and protective immunity at 90 days post pTS ± IL-15 vaccination. Female BALB/c mice were vaccinated i.m. 3
times, 2 weeks apart, with plasmid DNAs encoding TS (pTS) and/or IL-15 (pIL-15). Three months after the third and final vaccination, spleen cells from
representative mice were incubated for 16-20 hours in IFN-c ELISPOT assays in the presence of negative control antigen presenting cells (A20), or
antigen presenting cells stably transfected with full length TS (A20-TS). In addition, 5 mice per group were challenged with 5,000 BFT s.c. and survival
monitored for . 2 months. Mice vaccinated with pTS (regardless of inclusion of pIL-15) produced high numbers of TS-specific IFN-c secreting cells
detected 3 months following immunization (A, pooled cells from 2 mice per group). Additionally, 4 of 5 mice vaccinated with pTS and all 5 of the
mice vaccinated with pTS+pIL-15 survived systemic lethal T. cruzi challenge (B, * P,0.05 by Fisher’s exact tests in comparison to pIL-15 alone group).
Data representative of 3 experiments.
doi:10.1371/journal.pntd.0000983.g003
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to study protective immunity induced by the different vaccination
strategies, we challenged 5 mice per group with a lethal dose of T.
cruzi BFT (5,000 BFT s.c.) 30 days following the final
immunization, and followed survival for .2 months. All mice
vaccinated with pTS (with or without pIL-15 co-immunization)
survived lethal T. cruzi challenge, whereas all mice vaccinated with
pIL-15 alone died (Fig. 2B, P,0.05 comparing pIL-15 alone
group to pTS alone and pTS + pIL-15 vaccinated groups).
Figure 4. T cell responses and protective immunity at 6 months post pTS ± IL-15 vaccination. BALB/c mice were vaccinated i.m. 3 times,
2 weeks apart, with plasmids encoding TS (pTS) and/or IL-15 (pIL-15). (A) Six months after the final vaccination, spleen cells from representative mice
(4 mice per group) were incubated for 16-20 hours in IFN-c ELISPOT assays in the presence of negative control antigen presenting cells (NC A20), or
antigen presenting cells stably transfected with full length TS (A20-TS). Mice vaccinated with pTS + pIL-15 developed significantly increased numbers
of TS-specific IFN-c secreting cells compared with mice vaccinated with pTS alone (A*P,0.05 compared with the pIL-15 alone group, **P,0.05
compared with either the pIL-15 alone or pTS alone groups by Mann Whitney U tests). (B) In addition, 8–10 mice per group were challenged with
5,000 BFT s.c. and survival monitored for .2 months. Only 3 of 10 mice vaccinated with pTS alone, and none of 10 mice vaccinated with pIL-15 alone,
survived lethal T. cruzi challenges (differences not significant). In contrast, 7 of 8 mice vaccinated with pTS+pIL-15 survived T. cruzi BFT challenge
(P,0.05 comparing pTS+pIL-15 to pTS alone, and comparing pTS+pIL-15 to pIL-15 alone). Data representative of 2 experiments.
doi:10.1371/journal.pntd.0000983.g004
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Intermediate term immune responses and systemic
protection by pTS & pIL-15 vaccination
In mice three months after vaccination with plasmids
encoding TS and/or IL-15, we analyzed vaccine-induced TS-
specific T cell responses utilizing IFN-c ELISPOT assays and
induction of protective immunity against lethal T. cruzi challenge.
As shown in Fig. 3A., vaccination of mice with pTS alone or
pTS + pIL-15 elicited strong TS-specific T cell responses as
detected 3 months after vaccination. However, there was a trend
for higher frequencies of TS-specific IFN-c producing cells after
pTS co-immunization with pIL-15 (pTS + pIL-15.pTS alone
by .20%). There were no significant differences in TS-specific
serum IgG responses present in serum samples obtained from
pTS alone and pTS + pIL-15 vaccinated mice (endpoint titers of
.90,000 in pTS alone and pTS + pIL-15 samples compared to
,100 in pIL-15 alone vaccinated mice). Immunization of mice
with pTS alone and pTS + pIL-15 resulted in significantly
enhanced survival after challenge compared with pIL-15
immunization alone (Fig 3B, P,0.05). Additionally, although
not statistically significant, 4 of 5 mice vaccinated with pTS
alone survived lethal T. cruzi challenge compared with 5 of 5
mice vaccinated with pTS + pIL-15.
Long-term Protective Immunity induced by pTS & pIL-15
co-immunization
IL-15 is thought to enhance long term survival of memory T
cells, thus we explored long term T cell function in pTS alone
versus pTS + pIL-15 vaccinated mice. Six months following the
final immunization, we detected nearly twice as many TS-
specific IFN-c producing T cells in spleens from mice co-
immunized with pTS + pIL-15 compared with spleen cells
obtained from mice vaccinated with pTS alone (Fig. 4A, P,0.05
by Mann Whitney U test comparing pTS alone to pIL-15 +
pTS groups.). Vaccination with pTS alone and pTS + pIL-15
resulted in potent TS-specific serum IgG responses detected 6
months post immunization [endpoint titers in serum samples
from pTS alone and pTS+pIL-15 immunized mice were
.15,000 compared to ,100 in pIL-15 controls (P,0.05
comparing pTS alone and pTS+pIL-15 groups to pIL-15
control group)]. In addition, protective immunity induced by
pTS vaccination alone was significantly reduced 6 months after
vaccination, as demonstrated in Fig. 4B. Only 3 of 10 mice
vaccinated with pTS alone, and none of 10 mice vaccinated
with pIL-15 alone, survived lethal T. cruzi challenges (differences
not significant). In contrast, 7 of 8 mice vaccinated with pTS +
pIL-15 survived T. cruzi BFT challenge (P,0.05 comparing
pTS + pIL-15 to pTS alone, and comparing pTS + pIL-15 to
pIL-15 alone). Thus, addition of IL-15 to the TS vaccination
regimen significantly enhances long term survival against lethal
parasite challenge.
IL-15 induces long-term CD4+ and CD8+ T cell cytokine
production potential
After demonstrating that co-administration of pIL-15 with
pTS greatly enhances long-term protection against T. cruzi
challenge, we further dissected T cell responses induced by
vaccination with pTS alone compared with pTS + pIL-15. In
order to study T cell compartment cytokine production
potentials, we stimulated spleen cells from vaccinated mice (6
months after the 3rd and final vaccination) with PMA +
ionomycin, then analyzed the overall cytokine production in T
cells using intracellular flow cytometry. As seen in Table 1, in
general, pTS vaccination alone did not significantly alter CD4+
or CD8+ T cell profiles in comparison with control pIL-15
vaccinated mice in terms of IL-2, IFN-c, or TNF-a expression.
However, vaccination with pTS + pIL-15 resulted in significantly
increased frequencies of all cytokine parameters analyzed in both
CD4+ and CD8+ T cell compartments (IL-2, IFN-c, and TNF-a,
P,0.05 by Mann Whitney comparing pTS+pIL-15 to pTS alone
and pIL-15 alone). In addition, we detected significantly
increased frequencies of multi-parameter CD4+ and CD8+ T
cells which expressed IL-2 + IFN-c as well as TNF-a + IFN-c
(P,0.05 by Mann Whitney comparing pTS+pIL-15 to pTS
alone and pIL-15 alone).
IL-15 increases TS-specific, IFN-c producing CD8+ T cell
numbers and proliferative capacity
Both CD4+ and CD8+ T cells from mice vaccinated with
pTS + pIL-15 exhibited more potential for robust cytokine
production following polyclonal stimulation with PMA +
ionomycin than cells obtained from mice vaccinated with pTS
alone. In order to determine the frequencies of CD4+ and
CD8+ IFN-c producing TS-specific T cells at the late time point
in which we observed differential protective capacity against
lethal T. cruzi challenge, we cultured total spleen cells from
vaccinated mice overnight with APC transfected (or not) with
full length TS, then performed intracellular cytokine staining as
detailed above. We detected significant increases in frequencies
of CD4+ T cells producing IFN-c, TNF-a, and IL-2 upon A20-
TS stimulation in mice vaccinated with either pTS or pTS +
pIL-15 compared to mice vaccinated with control pIL-15
(P,0.05 by Wilcoxon matched pair and Mann-Whitney U
tests), however, there were no noticeable differences measured
between pTS alone and pTS + pIL-15 groups (Fig. S1). Similar
statistically significant increases in TS-specific IFN-c, IL-2, and
TNF-a producing cells amongst CD8+ T cells were observed in
pTS and pTS + pIL-15 vaccinated groups compared with the
pIL-15 control vaccinated group (Figs. 5A, B, and Fig. S2,
P,0.05 by Wilcoxon matched pair and Mann-Whitney U tests).
As shown in Figs. 5A and B, significantly more TS-specific IFN-
c+ splenic CD8+ T cells were detected in mice vaccinated 6
months prior with pTS + pIL-15 compared with mice
Table 1. Increased Type 1 phenotype of CD4+ and CD8+ T
cells 6 months after administration of pTS + pIL-15.
pIL-15 pTS pTS + pIL-15
CD4 gated, IL2+ 0.6660.22 0.9960.24 6.8360.51{
CD4 gated, IFNc+ 0.5460.16 0.5260.13 2.3960.33{
CD4 gated, TNFa+ 11.6463.27 9.5662.10 50.6461.99{
CD4 gated, IL2+IFNc+ 0.0960.03 0.1560.03 0.7460.07{
CD4 gated, TNFa+IFNc+ 0.3960.11 0.4360.10 1.8560.25{
CD8 gated, IL2+ 0.0460.00 0.0960.02 0.5360.09{
CD8 gated, IFNc+ 0.1960.06 0.3760.04 1.4560.11{
CD8 gated, TNFa+ 9.6262.53 8.6361.62 44.8262.10{
CD8 gated, IL2+IFNc+ 0.0160.01 0.0360.00 0.1360.03{
CD8 gated, TNFa+IFNc+ 0.1660.04 0.3260.04{ 1.1560.07{
Shown are frequencies of cytokine producing cells 6 months following
vaccination after PMA+ionomycin stimulation (mean6SE from N = 4–5 per
group).
{P,0.05 compared to pIL-15 alone vaccine group; { P,0.05 compared to pIL-15
and pTS vaccine groups.
doi:10.1371/journal.pntd.0000983.t001
IL-15-Adjuvanted T. cruzi Vaccine Studies
www.plosntds.org 8 March 2011 | Volume 5 | Issue 3 | e983
Figure 5. Persistent increases in CD8+ T cell frequencies and responsiveness after co-administration of pTS + pIL-15. BALB/c mice
were vaccinated three times, 2 weeks apart with pIL-15, pTS, or pIL-15+pTS. Six months later, spleen cells (N = 4/group) were cultured overnight with
negative control (NC A20) or TS-expressing APC (A20-TS), then ICS performed for quantitation of TS-specific IFN-c producing CD8+ T cells (A and B,
shown are frequencies of CD3+ T cells). Spleen cells from mice vaccinated with pTS + pIL-15 exhibited much higher frequencies of TS-specific IFN-c
expressing CD8+ T cells compared with spleen cells from mice vaccinated with pTS alone (representative results shown in A; cumulative data from 4
individual mice per group in B). In order to study expansion capacities of TS-specific CD8+ T cells, spleen cells from mice obtained 6 months post
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vaccinated with pTS alone (Fig 5A, FACS plots from
representative mice; Fig 5B, cumulative data from N = 4 mice
per group, P,0.05 by Mann Whitney U test).
Vaccination of BALB/c mice with pTS has previously been
shown to induce potent CD8+ T cell responses against the
immunodominant TS H2Kd-restricted peptide IYNVGQVSI. We
anticipated that we would observe higher frequencies of
TS(IYNVGQVSI)-specific T cells in pTS + pIL-15 vaccinated mice
compared with pTS alone vaccinated mice. However, even
though we observed statistically significant increases in frequencies
of CD8+ TS(IYNVGQVSI)/H2Kd tetramer-specific T cells 6 months
post vaccination in both pTS and pTS + pIL-15 immunized mice
compared with pIL-15 control vaccinated mice, we could not
detect differences between the pTS and pTS + pIL-15 vaccinated
groups (0.088%60.025 and 0.088%60.021 in pTS and pTS +
pIL-15 groups, respectively, compared with 0.035%60.005 in
pIL-15 control mice as determined by tetramer staining, P,0.05
by Mann Whitney). In order to analyze the proliferative capacity
of these TS(IYNVGQVSI)-specific CD8+ T cells after exposure to
antigen, we labeled spleen cells from vaccinated mice with CFSE
and stimulated these cells with irradiated APC stably transfected
(or not) with TS for 5 days prior to tetramer staining. As shown in
Fig. 5C, TS(IYNVGQVSI) -specific CD8+ spleen cells from pTS +
pIL-15 vaccinated animals expanded to greater frequencies and
absolute numbers compared with cells obtained from pTS alone
vaccinated mice (P,0.05 comparing pTS+pIL-15 and pIL-15
groups).
Trans-sialidase-specific CD8+ T cells alone can protect
against T. cruzi challenge
As total TS-specific IFN-c T cell responses were found to be
greatly increased after addition of pIL-15 to the pTS vaccination
regimen 6 months post-vaccination, and these increased responses
were associated with increased protection, we next sought to
investigate whether pTS-induced CD8+ T cells alone could
transfer protection against lethal T. cruzi challenge. The frequen-
cies of CD8+ T cells present in mice vaccinated with pTS DNA
with or without pIL-15 have not been sufficient to allow practical
adoptive transfer experiments to be done. We have recently found
that a strategy of boosting pTS responses with TS-expressing
adenovirus vaccinations results in up to 10-20 fold more TS-
specific CD8+ T cells. Therefore, we vaccinated BALB/c mice
with 2 doses of pTS DNA followed 1 month later with 2 doses of
Adeno-TS to obtain sufficient numbers of TS-specific CD8+ T
cells for adoptive transfer experiments. As shown in Fig. 6A, mice
vaccinated with pTS followed by Adeno-TS developed massive
CD8+ TS-specific IFN-c responses (.22,000 IFN-c spot forming
cells per million CD8+ T cells). We adoptively transferred 2.66107
CD8+ T cells obtained from negative control or TS prime/boost
vaccinated mice into naı¨ve BALB/c recipient mice followed by
challenge of these mice the following day with a lethal dose of T.
cruzi (5,000 BFT s.c.). As seen in Fig. 6B, mice adoptively
transferred with negative control T cells succumbed rapidly to T.
cruzi infection (100% mortality within 3 weeks). However, all of the
mice which received TS-specific CD8+ T cell transfers survived
lethal T. cruzi challenge (P , 0.05, Fisher’s exact test). Thus,
vaccine-induced TS-specific CD8+ T cells alone can protect
against lethal systemic T. cruzi challenge, and the increases in TS-
specific CD8+ T cell responses seen in mice vaccinated with pTS +
pIL-15 could be sufficient to explain the mechanism for prolonged
enhanced protection.
Discussion
The addition of IL-15 adjuvants to vaccine regimens has
previously been shown to enhance protective immunity against a
variety of pathogens, including influenza, Toxoplasma gondii, and
Herpes simplex virus (HSV) [22–24]. We have demonstrated here
that the addition of a plasmid DNA expressing murine IL-15 (pIL-
15) to a plasmid DNA vaccine encoding the T. cruzi trans-sialidase
(pTS) leads to significant enhancement of long-term protective
immunity against this complex intracellular protozoan pathogen.
The combination of pIL-15 and pTS induced significantly higher
levels CD4+ Th1 cells and TS-specific IFN-c producing CD8+ T
cells which displayed enhanced proliferative capacity after
antigenic restimulation compared with the levels of these responses
induced by vaccination with pTS alone. More importantly, these
TS-specific immune responses enhanced by IL-15 co-administra-
tion led to significant increases in protective immunity 6 months
post-vaccination.
IL-15 is a member of a family of common c chain (cc)-
dependent cytokines including IL-2, IL-4, IL-7, IL-9, IL-15 and
IL-21, which require expression of the cc receptor component for
functional cytokine signaling. The IL-15 and IL-2 receptor
complexes also share CD122 (IL-2Rb/IL-15Rb) resulting in very
similar in vitro effects of these 2 cytokines on the growth of NK
cells and different subsets of T cells. However, IL-15 signaling is
unique among the cc cytokines involving a plasma membrane/
endosomal recycling of the complex between IL-15 and its unique
IL-15Ra receptor component which results in the prolonged
capacity for IL-15 to signal in trans to cells expressing the cc/IL-
15Rb complex on their surface [25]. In contrast, efficient signaling
by soluble IL-2 requires binding to the high affinity IL-2R
complex (including CD25/cc/IL-2Rb) followed by receptor/
cytokine internalization and degradation of the IL-2 ligand.
Hence, IL-15 signaling is prolonged and dependent on cell-to-cell
contact while IL-2 signaling is more transient and requires active
IL-2 secretion by activated cells. These biological differences and
the distinct expression profiles of CD25 and IL-15Ra likely
explain the opposing effects of IL-15 and IL-2 identified in vivo
[26]. Deficiency of IL-15 leads to a profound depletion of NK
cells, NKT cells, intestinal intraepithelial lymphocytes and CD8+
memory T cells, whereas deficiency of IL-2 leads to lymphopro-
liferative and autoimmune disease. In addition, IL-15 has
overlapping functions with IL-7 important for the survival,
maintenance and homeostatic proliferation of both CD4+ and
CD8+ memory T cells [26].
The enhancing effects of IL-15 on memory T cell survival and
expansion have been viewed as reasons to investigate the potential
vaccine adjuvant effects of this cytokine. Our results showing that
significantly increased numbers of TS-specific CD8+ T cells persist
vaccination (N = 4 per group) were labeled with CFSE and co-cultured with irradiated negative control A20 or A20-TS APCs. On day 5, T cells were
stained for T cell surface markers including a tetramer reagent specific for TCR reactive with an immunodominant H2Kd-restricted epitope (TSKd1)
and studied by flow cytometry (gated on CD8+ T cells). Shown in Panel C are the absolute numbers of TSKd1-specific T cells (in upper left of FACS
plots), and the expansion indices of TSKd1-specific T cells detected in these assays (AN index = absolute number of TSKd1-specific cells after A20-TS
expansion 4 absolute number of TSKd1-specific cells after NC A20 expansion.) Vaccination with pTS + pIL-15 resulted in significant enhancement of
TSKd1–specific CD8+ T cell responses capable of lymphoproliferative expansion. (* P,0.05 in comparison with pIL-15 alone group, ** P,0.05 in
comparison with pIL-15 alone and pTS alone vaccine groups by Mann Whitney U tests.) Data representative of 2 experiments.
doi:10.1371/journal.pntd.0000983.g005
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6 months after vaccination with pTS plus pIL-15 compared with
vaccination with pTS alone (Figure 5) are consistent with the
known T cell survival and homeostatic proliferative effects
promoted by IL-15. These effects could be due to survival effects
triggered in the presence of increased IL-15 during the initial TS-
specific T cell activation or maintenance effects provided by
prolonged production of IL-15. We were unable to detect
increased IL-15 in the serum of mice 6 months post-vaccination
with pTS plus pIL-15 (data not shown), but these results do not
rule out the possibility that persistence and/or prolonged recycling
of surface bound IL-15 occurs on professional antigen presenting
cells (e.g. monocytes and/or dendritic cells) expressing the IL-
15Ra chain as reviewed above. This would be hard to disprove
since IL-15 trans signaling has been shown to provide a highly
potent mechanism of signaling through both IL-15Ra/IL-15Rb/
cc trimeric and IL-15Rb/cc dimeric receptor complexes, active
Figure 6. Vaccine-induced TS-specific CD8+ T cells mediate protection against lethal systemic T. cruzi challenge. BALB/c mice were
vaccinated with 100 mg of pTS alone i.m. on days 0 and 14 followed by 16108 pfu Adeno-TS s.c. on days 42 and 56 (A and B, data representative of 4
experiments). Two months later, immunomagnetically purified splenic CD8+ T cells from vaccinated mice were stimulated with negative control or
TS-expressing APC (A20 and A20-TS) in IFN-c ELISPOT assays (A). Mice vaccinated with pTS followed by Adeno-TS developed greatly increased CD8+
TS-specific IFN-c responses (.20,000 SFC/million). CD8+ T cells obtained from negative control or TS prime-boost vaccinated mice were injected i.p.
into naı¨ve BALB/c recipient mice (2.66107 per mouse). These adoptively transferred mice were challenged the following day with 5,000 T. cruzi BFT
s.c. (N = 4 mice per group; B). Mice adoptively transferred with negative control T cells succumbed rapidly to T. cruzi infection. However, all mice
which received TS-specific CD8+ T cell transfers survived lethal T. cruzi challenge (* P,0.05, Fisher’s exact test).
doi:10.1371/journal.pntd.0000983.g006
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with subpicomolar concentrations of IL-15 [25]. Longer-term and
more detailed studies are required to evaluate the maximal
duration of the enhancing effects of our pIL-15 adjuvant, and to
determine the associated period of time of enhanced IL-15
signaling.
In addition to enhancing TS-specific CD8+ T cell responses, we
report that the pIL-15 adjuvant enhanced TS-specific CD4+ T cell
responses induced by pTS vaccination (Table 1). Enhanced TS-
specific CD4+ memory T cell could provide functions in addition to
TS-specific CD8+ memory T cell responses protective against T.
cruzi challenges. Enhanced CD4+ T cells could provide improved
helper function for induction of protective CD8+ T cells and/or TS-
specific antibody responses capable of targeting the extracellular
blood form trypomastigote life stage for destruction. In support of an
important role for CD4+ T cell responses in the IL-15 enhanced
protective effects, we were unable to induce protection in CD4
knockout mice vaccinated with the combination of pTS plus pIL-15
(data not shown). However, enhancement of CD4+ T cells alone
cannot fully explain the IL-15 enhanced T. cruzi protective
immunity. We have shown previously that T. cruzi-specific CD4+
T cells alone cannot transfer protective T. cruzi immunity [27].
As mentioned above, enhanced expansion and survival of CD4+
memory T cells could provide greater helper effects for TS-specific
B cell responses. Alternatively, it is possible that IL-15 could directly
enhance antibody responses by signaling through the IL-15Ra
known to be expressed on activated B cells [28]. Furthermore, IL-15
has been demonstrated to stimulate proliferation and antibody
secretion in B cells facilitated by the inhibition of FAS-mediated
apoptosis [29]. However, it seems unlikely that the TS-specific B
cell/antibody responses were responsible for the pIL-15-enhanced
long-term protection against parasite challenge. We observed
potent TS-specific antibody responses 6 months after vaccination
in mice given pTS alone, but these mice were not protected against
lethal T. cruzi challenge. Furthermore, we have shown previously
that vaccination of B cell knockout mice with pTS alone confers
protection against T. cruzi challenge [3]. Thus, antibody responses
do not seem to be the likely mediator of enhanced protective
immunity induced by IL-15 and TS encoding plasmid vaccines.
Regardless of the possible roles of TS-specific CD4+ T cell and
antibody responses, the pIL-15-enhanced long-term protective
immunity clearly involves important effects on CD8+ memory T
cells. In fact, we believe the effects of IL-15 on CD8+ T cell
responses are likely to represent the most important effects
responsible for enhancing protective T. cruzi immunity. Other
investigators have shown that T. cruzi-specific CD8+ T cells alone
can transfer protection [30,31], and we demonstrate here that TS-
specific CD8+ T cell responses alone can transfer protective
immunity (Figure 6). The addition of pIL-15 to pTS vaccination
significantly increased CD8+ T cell responses (IFN-c+, TNF-a+,
IL-2+) detectable 6 months post-vaccination (Figure 5 and
Table 1). In addition, TS-specific memory CD8+ T cells primed
by pTS and pIL-15 displayed enhanced lymphoproliferative
capacity after antigen re-exposure detectable in CFSE dilution
assays (Figure 5C.). Although we were unable to detect differences
in memory markers (CCR7, CD62L, and CD127, data not shown)
expressed on total and H2Kd/TSIYNVGQVSI-specific T cells
obtained from pTS and pIL-15 + pTS vaccinated mice, the
combination of enhanced proliferative and effector functions
suggests that both central memory (memory T cells with optimal
proliferative capacity) and effector memory (expressing optimal
immediate effector functions) were improved by the addition of the
pIL-15 adjuvant. Further investigations will need to evaluate the
relative importance of different subsets of CD8+ memory T cell
responses for IL-15 enhanced protective T. cruzi immunity.
We were impressed by the enormous differences in PMA/
ionomycin-induced cytokine responses in both CD4+ and CD8+ T
cells primed by the combination of pTS plus pIL-15 compared with
priming by either pTS or pIL-15 alone (Table 1). We detected 4–10
fold increased frequencies of T cells capable of producing IFN-c,
TNF-a, and/or IL-2 after pTS plus pIL-15 vaccination compared
with either pTS or pIL-15 given alone. In fact, over 50% of CD4+ T
cells from pTS plus pIL-15 vaccinated mice produced TNF-a after
PMA/ionomycin stimulation (compared with ,12% of CD4+ T
cells from mice vaccinated with pTS or pIL-15 alone). We must
emphasize that this remarkable enhancement of polyclonal T cell
responses required immunization with both pTS and pIL-15 and
was not seen in mice vaccinated only with pIL-15. Total
percentages and numbers of CD44+ memory CD4+ and CD8+ T
cells were nearly identical in pIL-15 alone, pTS alone and pIL-15
plus pTS vaccinated mice (data not shown), indicating that
enhanced cytokine responsiveness in pIL-15 plus pTS vaccinated
mice was not due simply to an IL-15-induced expansion of pre-
existing polyclonal memory T cells. Overall, these results suggest
that in the context of antigen-specific stimulation of T cell responses
in vivo, increased levels of IL-15 could result in a marked shift of
polyclonal T cells into a more activated state with enhanced
responsiveness to inflammatory stimuli. Theoretically, this effect
could result in a more broadly reactive epitope spreading of immune
responses important for optimal vaccine-induced protection against
pathogens with high potential for epitope mutational escape. On the
other hand, this increased polyclonal T cell responsiveness could
lead to increased risks of autoimmunity or immune-mediated
inflammatory disease as adverse effects associated with IL-15
adjuvanted vaccinations or immunotherapies. Future studies will
need to explore these possibilities in detail.
In summary, our results demonstrate that a plasmid expressing
IL-15 can have significant adjuvant effects for induction of
enhanced protective T. cruzi immunity and suggest important
mechanistic explanations for these effects that should be further
analyzed in future research.
Supporting Information
Figure S1 TS-specific CD4+ T cell responses 6 months following
pTS6pIL-15 vaccination. BALB/c mice were vaccinated three
times, 2 weeks apart with pIL-15, pTS, or pIL-15 + pTS. Six
months later, spleen cells (N = 4/group) were cultured overnight
with negative control (NC A20) or TS-expressing APC (A20-TS),
then ICS performed for quantitation of TS-specific IL-2, IFN-c
and TNF-a producing CD4+ T cells. Shown are frequencies of
cytokine producing T cells after A20-TS stimulation (gated on
CD4+ cells, NC A20 stimulation values subtracted). Vaccination
with pTS alone or with pIL-15 + pTS induced significantly higher
frequencies of IL-2, IFN-c, and TNF-a-producing CD4+ T cells
compared to vaccination with pIL-15 alone (* P,0.05 in
comparison with pIL-15 alone group).
Found at: doi:10.1371/journal.pntd.0000983.s001 (0.14 MB TIF)
Figure S2 TS-specific CD8+ T cell responses 6 months following
pTS6pIL-15 vaccination. BALB/c mice were vaccinated three
times, 2 weeks apart with pIL-15, pTS, or pIL-15 + pTS. Six
months later, spleen cells (N = 4/group) were cultured overnight
with negative control (NC A20) or TS-expressing APC (A20-TS),
then ICS performed for quantitation of TS-specific IL-2 and TNF-
a producing CD8+ T cells. Shown are frequencies of cytokine
producing T cells after A20-TS stimulation (gated on CD8+ T
cells, NC A20 stimulation values subtracted). Vaccination with
pTS alone or with pIL-15 + pTS induced significantly higher
frequencies of IL-2 and TNF-a-producing CD8+ T cells compared
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to vaccination with pIL-15 alone (* P,0.05 in comparison with
pIL-15 alone group).
Found at: doi:10.1371/journal.pntd.0000983.s002 (0.24 MB TIF)
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